bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
Company profile
Ticker
BCYC
Exchange
Website
CEO
Kevin Lee
Employees
Location
Fiscal year end
Industry (SIC)
Former names
BICYCLE THERAPEUTICS Ltd
SEC CIK
BCYC stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
20 Feb 24
8-K
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
14 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
2 Nov 23
8-K
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
11 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
8-K
Entry into a Material Definitive Agreement
13 Jul 23
Latest ownership filings
4
Michael Charles Ferguson Hannay
21 Mar 24
3
Michael Charles Ferguson Hannay
21 Mar 24
4
Stephen H. Sands
21 Feb 24
3
Stephen H. Sands
21 Feb 24
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G
Jefferies Financial Group Inc.
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
BAKER BROS. ADVISORS LP
12 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm | 572.63 mm |
Cash burn (monthly) | (no burn) | (no burn) | 16.93 mm | 13.99 mm | 341.67 k | 3.64 mm |
Cash used (since last report) | n/a | n/a | 101.17 mm | 83.61 mm | 2.04 mm | 21.73 mm |
Cash remaining | n/a | n/a | 471.46 mm | 489.02 mm | 570.59 mm | 550.90 mm |
Runway (months of cash) | n/a | n/a | 27.8 | 34.9 | 1670.0 | 151.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 24 |
Closed positions | 9 |
Increased positions | 36 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 634.19 bn |
Total shares | 36.99 mm |
Total puts | 73.80 k |
Total calls | 27.70 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
Paradigm Biocapital Advisors | 3.64 mm | $73.17 bn |
Deep Track Capital | 3.49 mm | $70.12 bn |
First Light Asset Management | 2.07 mm | $41.60 bn |
JEF Jefferies Financial | 1.95 mm | $39.14 bn |
MS Morgan Stanley | 1.62 mm | $32.58 bn |
SVLSF V | 1.56 mm | $54.41 mm |
GSK GSK | 1.53 mm | $39.40 mm |
Point72 Asset Management | 1.30 mm | $26.11 bn |
Braidwell | 1.29 mm | $25.91 bn |
Tybourne Capital Management | 1.28 mm | $25.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Michael Charles Ferguson Hannay | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 24.12 | 58,000 | 1.40 mm | 58,000 |
6 Feb 24 | Arroyo Santiago | Ordinary Shares | Grant | Acquire A | No | No | 0 | 21,660 | 0.00 | 39,000 |
6 Feb 24 | Arroyo Santiago | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 17 | 41,570 | 706.69 k | 41,570 |
3 Jan 24 | Nigel Crockett | Ordinary Shares | Sell | Dispose S | No | No | 17.5 | 2,643 | 46.25 k | 48,716 |
2 Jan 24 | Nigel Crockett | Ordinary Shares | Grant | Acquire A | No | No | 0 | 22,000 | 0.00 | 51,359 |
2 Jan 24 | Nigel Crockett | Employee Stock Option Ordinary Shares | Grant | Acquire A | No | No | 18.08 | 44,000 | 795.52 k | 44,000 |
News
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
21 Feb 24
Canaccord Genuity Reiterates Buy on Bicycle Therapeutics, Maintains $60 Price Target
21 Feb 24
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
21 Feb 24
HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $55
21 Feb 24
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
21 Feb 24